个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Meiting Chen[1] * ; Lu Li[1] * ; Qing Xia[2] * ; Xiaobing Chen[3] ; Zijun Liao[4] ; Chang Wang[5] ; Bo Shen[6] ; Min Zhou[7] ; Qingyuan Zhang[8] ; Yanqiao Zhang[8] ; Liting Qian[9] ; Xianglin Yuan[10] ; Zhehai Wang[11] ; Cong Xue[1] ; Xin An[1] ; Bin Liu[12] ; Kangsheng Gu[13] ; Mei Hou[14] ; Xiaojia Wang[15] ; Wei Wang[16] ; Enxiao Li[17] ; Jincai Zhong[18] ; Jing Cheng[19] ; Yongqian Shu[20] ; Nong Yang[21] ; Huaqing Wang[22] ; Runxiang Yang[23] ; Tianshu Liu[24] ; Ting Deng[25] ; Fei Ma[26] ; Wangjun Liao[27] ; Wensheng Qiu[28] ; Yu Chen[29] ; Xi Chen[30] ; Mingzhi Zhang[31] ; Ruilian Xu[32] ; Xiaoling Li[33] ; Jifeng Feng[6,*1] ; Yi Ba[25,*2] ; Yanxia Shi[1,*3] ;
机构： [1]Department of Medical Oncology, State Key Laboratory of Oncology in SouthChina, Sun Yat‐sen University Cancer Center, Guangzhou, China [2]Department of Oncology, Renji Hospital, Medical College of Shanghai JiaotongUniversity, Shanghai, China [3]Departement of Oncology, The Affiliated Cancer Hospital of ZhengzhouUniversity, Henan Cancer Hospital, Zhengzhou, China [4]Departement of Medical Oncology, Shaanxi Cancer Hospital, Xi’an, China [5]Department of Cancer Center, First Hospital of Jilin University, Changchun,China [6]Department of Oncology, Jiangsu Cancer Institute, Nanjing, China [7]Internal Medicine, Affiliated Cancer Hospital and Institute of GuangzhouMedical University, Guangzhou, China [8]Department of Oncology, Harbin Medical University Cancer Hospital, Harbin,China [9]Division of Life Sciences and Medicine, Department of Radiation Oncology, TheFirst Affiliated Hospital of University of Science and Technology of China, Hefei,China [10]Department of Oncology, Cancer Center of Union Hospital, HuazhongUniversity of Science and Technology, Wuhan, China [11]Department of Respiratory Medicine, Shandong Cancer Hospital andInstitute, Shandong First Medical University and Shandong Academy of MedicalSciences, Jinan, China [12]Internal Medicine, Sichuan Cancer Hospital and Institute, Sichuan CancerCenter, School of Medicine, University of Electronic Science and Technology ofChina, Chengdu, China [13]Department of Oncology, The First Affiliated Hospital of Anhui MedicalUniversity, Hefei, China [14]Lung Cancer Center, West China Hospital of Sichuan University, Chengdu,China [15]Department of Breast Medical Oncology, Zhejiang Cancer Hospital,Hangzhou, China [16]Internal Medicine, First People's Hospital of Foshan, Foshan, China [17]Department of Medical Oncology, The First Affiliated Hospital of Xi'anJiaotong University Medical College, Xi'an, China [18]The First Affiliated Hospital of Guangxi Medicine University, Nanning, China [19]Cancer Center of Union Hospital, Huazhong University of Science andTechnology, Wuhan, China [20]Department of Oncology, Jiangsu Province Hospital, Nanjing MedicalUniversity, Nanjing, China [21]Department of Pharmacy, Hunan Cancer Hospital, Changsha, China [22]Department of Medical Oncology, Tianjin People's Hospital, Tianjin, China [23]Department of Oncology, Yunnan Cancer Hospital, The Third AffiliatedHospital of Kunming Medical College, Kunming, China [24]Department of Medical Oncology, Zhongshan Hospital, Fudan University,Shanghai, China [25]Department of Gastrointestinal Medical Oncology, Tianjin Medical UniversityCancer Institute and Hospital, National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical ResearchCenter for Cancer, Tianjin, China [26]Internal Medicine, Cancer Hospital of the Chinese Academy of MedicalSciences, Beijing, China [27]Internal Medicine‐Oncology, Southern Medical University Nanfang Hospital,Guangzhou, China [28]The Second Department of Oncology, Affiliated Hospital of QingdaoUniversity, Qingdao, China [29]Department of Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China [30]Department of Medical Oncology, Fuzhou General Hospital of NanjingMilitary Command, Fuzhou, China [31]Department of Oncology, The First Affiliated Hospital of ZhengzhouUniversity, Zhengzhou, China [32]Department of Medical Oncology, Shenzhen People's Hospital, Shenzhen,China [33]Department of Thoracic Cancer 1, Cancer Hospital of China MedicalUniversity, Liaoning Cancer Hospital and Institute, Shenyang, China
出处：
DOI： 10.1002/cncr.35292
ISSN：

关键词： cancer treatment–induced thrombocytopenia chemotherapy‐induced thrombocytopenia cross‐sectional study recombinant interleukin 11 recombinant thrombopoietin thrombopoietic agents thrombopoietin receptor agonist

摘要：
Studies on various thrombopoietic agents for cancer treatment-induced thrombocytopenia (CTIT) in China are lacking. This study aimed to provide detailed clinical profiles to understand the outcomes and safety of different CTIT treatment regimens.In this retrospective, cross-sectional study, 1664 questionnaires were collected from 33 hospitals between March 1 and July 1, 2021. Patients aged >18 years were enrolled who were diagnosed with CTIT and treated with recombinant interleukin 11 (rhIL-11), recombinant thrombopoietin (rhTPO), or a thrombopoietin receptor agonist (TPO-RA). The outcomes, compliance, and safety of different treatments were analyzed.Among the 1437 analyzable cases, most patients were treated with either rhTPO alone (49.3%) or rhIL-11 alone (27.0%). The most common combination regimen used was rhTPO and rhIL-11 (10.9%). Platelet transfusions were received by 117 cases (8.1%). In multivariate analysis, rhTPO was associated with a significantly lower proportion of platelet recovery, platelet transfusion, and hospitalization due to chemotherapy-induced thrombocytopenia (CIT) than rhIL-11 alone. No significant difference was observed in the time taken to achieve a platelet count of >100 × 109/L and chemotherapy dose reduction due to CIT among the different thrombopoietic agents. The outcomes of thrombocytopenia in 170 patients who received targeted therapy and/or immunotherapy are also summarized. The results show that the proportion of platelet recovery was similar among the different thrombopoietic agents. No new safety signals related to thrombopoietic agents were observed in this study. A higher proportion of physicians preferred to continue treatment with TPO-RA alone than with rhTPO and rhIL-11.This survey provides an overview of CTIT and the application of various thrombopoietic agents throughout China. Comparison of monotherapy with rhIL-11, rhTPO, and TPO-RA requires further randomized clinical trials. The appropriate application for thrombopoietic agents should depend on the pretreatment of platelets, treatment variables, and risk of bleeding.To provide an overview of the outcome of cancer treatment-induced thrombocytopenia in China, our cross-sectional study analyzed 1437 cases treated with different thrombopoietic agents. Most of the patients were treated with recombinant interleukin 11 (rhIL-11) and recombinant thrombopoietin (rhTPO). rhTPO was associated with a significantly lower proportion of platelet recovery and platelet transfusion compared with rhIL-11.© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

基金：
This work was supported by grants from National Key Research and Development Program of China (2021YFE0206300), and the Natural Science Foundation of China (82073391 and 81773279).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, State Key Laboratory of Oncology in SouthChina, Sun Yat‐sen University Cancer Center, Guangzhou, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Medical Oncology, State Key Laboratory of Oncology in SouthChina, Sun Yat‐sen University Cancer Center, Guangzhou, China [6]Department of Oncology, Jiangsu Cancer Institute, Nanjing, China [25]Department of Gastrointestinal Medical Oncology, Tianjin Medical UniversityCancer Institute and Hospital, National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical ResearchCenter for Cancer, Tianjin, China [*1]Department of Oncology, Jiangsu Cancer Institute, No. 42 Baiziting, Kunlun Rd, Xuanwu Dist, Nanjing 210009, China [*2]Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China [*3]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651, Dongfeng East Rd, Yuexiu Dist, Guangzhou 510060, China
推荐引用方式(GB/T 7714)：
Meiting Chen,Lu Li,Qing Xia,et al.A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study[J].CANCER.2024,130:1524-1538.doi:10.1002/cncr.35292.
APA：
Meiting Chen,Lu Li,Qing Xia,Xiaobing Chen,Zijun Liao...&Yanxia Shi.(2024).A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.CANCER,130,
MLA：
Meiting Chen,et al."A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study".CANCER 130.(2024):1524-1538

相关文献

[1]Effectiveness and economic evaluation of rhTPO and rhIL-11 in the treatment of cancer therapy induced thrombocytopenia based on real-world research [2]基因重组人白细胞介素-11治疗化疗所致血小板减少症临床研究 [3]重组人血小板生成素治疗化疗后血小板减少的临床观察 [4]A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. [5]特比奥与巨和粒治疗恶性实体瘤化疗后血小板减少的临床疗效比较 [6]Status and associated factors of cross-regional healthcare-seeking among patients with advanced colorectal cancer in China: a multicenter cross-sectional study [7]特比奥与巨和粒治疗恶性实体瘤化疗后血小板减少的临床疗效比较 [8]Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial [9]Shock in China 2018 (SIC-study): a cross-sectional survey [10]Inverted U-Shaped Associations between Glycemic Indices and Serum Uric Acid Levels in the General Chinese Population: Findings from the China Cardiometabolic Disease and Cancer Cohort (4C) Study

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号